Histogen Inc logo

HSTO - Histogen Inc News Story

$0.723 0.0  1.1%

Last Trade - 19/10/21

Sector
Healthcare
Size
Micro Cap
Market Cap £21.7m
Enterprise Value £4.17m
Revenue £1.03m
Position in Universe 6371st / 7245

Histogen to Report Third Quarter 2020 Earnings on November 12, 2020

Wed 28th October, 2020 8:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201028:nGNX37NFD9


SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a
clinical-stage therapeutics company focused on developing potential
first-in-class restorative therapeutics that ignite the body’s natural
process to repair and maintain healthy biological function, today announced
that Histogen’s financial results for the third quarter ended September 30,
2020 will be released after the close of market on Thursday, November 12,
2020.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing
potential first-in-class restorative therapeutics that ignite the body’s
natural process to repair and maintain healthy biological function.
Histogen’s innovative technology platform utilizes cell conditioned media
and extracellular matrix materials produced by hypoxia-induced multipotent
cells. Histogen’s proprietary, reproducible manufacturing process provides
targeted solutions across a broad range of therapeutic indications including
hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk
repair. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/5a42687c-9cb2-4dbf-960e-60f9776dd598)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.